Metropolis Healthcare - Nov 25, 2020 - Angel Broking

Mr. Keshav Lahoti - Associate Equity Analyst, Angel Broking Ltd

"Metropolis Healthcare is a leading Pathology centre in India. Company has an asset light model with a strong balance sheet. New guidelines issued by Maharashtra Government for travellers entering in the state from Delhi, Rajasthan,Gujarat and Goa will have to compulsorily undergo RT PCR test is positive for the business of the company. Due to Covid-19, the company is doing better business than in the non-Covid environment as testing such as RT PCR and antibody is leading to increased revenue and profitability for the company. Non covid business portfolio is close to normalcy and is in improving trend MoM. We continue to have a buy rating on the company by revising target price upwards to Rs. 2593 by valuing it at 36x EV/EBIDTA FY22E."

Source : Equity Bulls

Keywords